From: Ezrin overexpression predicts the poor prognosis of gastric adenocarcinoma
Clinical features | No. of cases | Strongly positive cases (%) | P-value |
---|---|---|---|
Age | |||
 <50 | 96 | 60 (62.5%) | NS |
 51-69 | 181 | 92 (50.8%) | |
 ≥70 | 29 | 16 (55.2%) | |
Gender | Â | Â | NS |
 Male | 164 | 102 (62.2%) | |
 Female | 113 | 66 (58.4%) | |
Lauren Types | Â | Â | <0.05, a |
 Intestinal type | 117 | 77 (65.8%) | |
 Diffuse type | 139 | 85 (61.2%) | |
 Mixed type | 21 | 6 (28.6%) | |
WHO’s Histological Types |  |  | NS |
 Well-diff. ade. | 85 | 42 (49.4%) | |
 Moderately-diff. ade. | 103 | 54 (52.4%) | |
 Poorly-diff. ade. | 59 | 50 (84.7%) | |
 Undifferentiated ade. | 5 | 3 (60.0%) | |
 Signet ring cell carcinoma | 9 | 5 (55.6%) | |
 Mucinous ade. | 16 | 14 (87.5%) | |
LN Metastasis | Â | Â | <0.01 |
 Negative | 151 | 53 (35.1%) | |
 Positive | 126 | 115 (91.3%) | |
Clinical Stage | Â | Â | <0.05, b |
 0 | 39 | 14 (35.9%) | |
 IA | 47 | 12 (25.5%) | |
 IB | 51 | 23 (45.1%) | |
 II | 75 | 59 (78.7%) | |
 IIIA | 59 | 54 (91.5%) | |
 IV | 6 | 6 (100%) | |
Disease Free Survival | Â | Â | <0.01 |
 ≥3 years | 152 | 53 (34.9%) |  |
 <3 years | 125 | 115 (92.0%) |  |